Skip to main navigation
Skip to search
Skip to main content
Hong Kong Baptist University Home
Help & FAQ
Home
Scholars
Departments / Units
Research Output
Projects / Grants
Prizes / Awards
Activities
Press/Media
Student theses
Datasets
Search by expertise, name or affiliation
View Scopus Profile
Kam Wa CHAN, Prof
Assistant Professor
,
Chinese Medicine - Teaching and Research Division
Associate Director
,
Vincent V.C. Woo Chinese Medicine Clinical Research Institute
https://orcid.org/0000-0002-3175-1574
Email
chriskwc
hkbu.edu
hk
Accepting PhD Students
2011
2025
Research activity per year
Overview
Fingerprint
Network
Projects / Grants
(2)
Research Output
(43)
Prizes / Awards
(1)
Activities
(37)
Similar Scholars
(6)
Fingerprint
Dive into the research topics where Kam Wa CHAN is active. Topic labels come from the works of this scholar. Together they form a unique fingerprint.
Sort by:
Weight
Alphabetically
Keyphrases
Acute Kidney Injury
27%
Adverse Events
26%
Albumin-to-creatinine Ratio
22%
Aliskiren
18%
Astragalus
18%
Catenin
27%
China
18%
Chinese Herbal Medicine
19%
Chinese Medicine
75%
Chinese Medicine Treatment
14%
Chronic Kidney Disease
53%
Chronic Kidney Disease Patients
19%
Clinical Trial Design
18%
Complementary and
12%
Complementary Medicine
12%
Confidence Interval
16%
COVID-19
40%
COVID-19 Vaccine
18%
Diabetes
36%
Diabetic Kidney Disease
50%
Diabetic Nephropathy
28%
Direct Renin Inhibition
18%
Estimated Glomerular Filtration Rate
33%
Hazard Ratio
14%
Hong Kong
15%
Hospital Registry
18%
IgA Nephropathy (IgAN)
18%
Immunogenicity
18%
Integrative Medicine
42%
Kidney Injury
19%
Kidney Transplant Recipients
17%
Medicine Services
16%
Meta-analysis
55%
Parkinson's Disease
18%
Pragmatic Clinical Trial
36%
Randomized Controlled Trial
27%
Rehmannia
18%
Renal Fibrosis
14%
Renal Function
12%
Renal Replacement Therapy
25%
Renal Tubule
23%
Retrospective Cohort Study
31%
Subgroup Analysis
11%
Systematic Meta-analysis
55%
Traditional Chinese Medicine
20%
Traditional Medicine
14%
Tubulointerstitial Fibrosis
18%
Type 2 Diabetes Mellitus (T2DM)
19%
Type 2 Diabetic Patients
15%
Western Medicine
28%
Medicine and Dentistry
Acute Kidney Injury
27%
Acute Renal Failure
11%
Adjuvant Therapy
11%
Adverse Event
25%
Astragalus
18%
Catenin
18%
Cell Death
9%
Chinese Herbal Medicine
19%
Chronic Kidney Disease
61%
Clinical Trial
37%
Clinical Trial Design
11%
Clinician
14%
Complement Component C5a
9%
Complementary Medicine
12%
COVID-19
37%
Creatinine
26%
Diabetes
44%
Diabetes Mellitus
14%
Diabetic Nephropathy
28%
Downregulation
14%
Fibrosis
20%
Glomerular Filtration Rate
34%
Hazard Ratio
14%
Herbal Agent
9%
Homeopathy
10%
Integrative Medicine
42%
Kidney Fibrosis
15%
Kidney Function
29%
Kidney Injury
19%
Lipid Metabolism
10%
Maturity Onset Diabetes of the Young
19%
Medicine
46%
Meta-Analysis
39%
Nephropathy
19%
Nuclear RNA
9%
Nucleotide Binding Oligomerization Domain Like Receptor
9%
Parkinson's Disease
18%
Patient with Type 2 Diabetes
14%
Periodontitis
9%
Placebo
9%
Post-Hoc Analysis
10%
Randomized Controlled Trial
51%
Retrospective Cohort Study
30%
Side Effect
9%
Stroke Rehabilitation
9%
Subgroup Analysis
10%
Systematic Review
55%
Traditional Chinese Medicine
100%
Traditional Medicine
14%
Vorapaxar
9%
Pharmacology, Toxicology and Pharmaceutical Science
Acetic Acid Derivative
9%
Acute Kidney Failure
18%
Adverse Event
32%
Aliskiren
18%
Aspartic Acid
9%
Astragalus
18%
Atrasentan
9%
Breast Cancer
9%
Captopril
9%
Catenin
9%
Chemotherapy
9%
Chronic Kidney Failure
75%
Chronic Obstructive Lung Disease
9%
Clinical Trial
25%
Cohort Study
27%
Complement Component C5a
9%
Coronavirinae
18%
COVID-19 Vaccine
18%
Creatinine
25%
Cytidine Phosphate
9%
Diabetes Mellitus
12%
Diabetic Nephropathy
36%
Diseases
25%
Endothelin Receptor Antagonist
9%
Fibrosis
21%
Herbal Agent
9%
Immunogenicity
18%
Immunoglobulin A Nephropathy
18%
Inflammation
24%
Kidney Fibrosis
15%
Kidney Injury
9%
Multiinfarct Dementia
9%
Network Pharmacology
11%
Non Insulin Dependent Diabetes Mellitus
19%
Parkinson's Disease
18%
Periodontitis
9%
Placebo
9%
Proline
9%
Proteinase Activated Receptor 1
9%
Randomized Controlled Trial
43%
Rehmannia
9%
Renal Diabetes
10%
Renin Inhibitor
18%
Replacement Therapy
25%
SARS Coronavirus
9%
Side Effect
9%
Tablet
9%
Traditional Chinese Medicine
44%
Ureter Obstruction
11%
Vorapaxar
9%